Biotech | April 12, 2022
ReiThera and Exothera collaborate to develop large-scale, low cost per dose vaccine
Collaboration awarded €3 million grant by the Bill & Melinda Gates Foundation
Collaboration awarded €3 million grant by the Bill & Melinda Gates Foundation
Collaboration to target bacterial and viral pathogens including HIV, SARS-CoV-2, antimicrobial-resistant pathogens, and tuberculosis
If authorized by the USFDA, the Proof Lab Test System may be used to deliver accurate, actionable, lab-quality results for Covid-19 in as little as 18 minutes
The initial SARS-CoV-2 research program at Calibr, the drug discovery and development division of Scripps Research, was supported by funding from the Bill & Melinda Gates Foundation
The immunogens being tested in IAVI G002 were developed by scientific teams at IAVI and Scripps Research and will be delivered via Moderna's mRNA technology
It plans to deliver over 300 million doses to the Indian government
Market demand for significant volumes and quality of biopharma products would drive continuous manufacturing technologies
The test combines sensitivity with speed and is designed to be used in health care settings to aid with rapid diagnosis of Covid-19
Advance to Phase 3 follows positive interim Phase 1/2 immunogenicity and safety data. The global clinical trial will evaluate vaccine candidate GBP510 against the AZ/Oxford COVID-19 vaccine
Subscribe To Our Newsletter & Stay Updated
